3 results
To determine the rate of detection of sub-clinical atrial AF (* 5 minutes) within an average of 12 months following implant of the Confirm® Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement,…
The primary objective is to measure the availability of the PDE10A enzyme in Huntington*s Disease (HD)gene expansion carriers (HDGECs) by estimating and comparing the distribution volume (VT) of the radioligand [18F]MNI-659 in the striatum (caudate…
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…